DPP4 and Miyoshi myopathy: These results suggest that huCD26mAb induces significant ADCC against MM cells, regardless of sensitivity or resistance to conventional or novel agents, and that the addition of novel agents to huCD26mAb increased sensitivity to huCD26mAb-induced ADCC against CD26+ MM cells.